{"id":450002,"date":"2021-03-03T16:08:20","date_gmt":"2021-03-03T21:08:20","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=450002"},"modified":"2021-03-03T16:08:20","modified_gmt":"2021-03-03T21:08:20","slug":"clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences\/","title":{"rendered":"Clene Nanomedicine to Present at Upcoming Virtual Investor Conferences"},"content":{"rendered":"
\n

SALT LAKE CITY, March 03, 2021 (GLOBE NEWSWIRE) — Clene Inc.<\/a> (NASDAQ: CLNN) (along with its subsidiaries, \u201cClene\u201d) today announced that its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of neurodegenerative disease using nanocatalysis, will present at the following upcoming investor conferences:<\/p>\n

\n H.C. Wainwright Global Life Sciences Conference<\/strong>
\n
A pre-recorded presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. ET on March 9, 2021.<\/p>\n

\n 33<\/strong>
\n
\n rd<\/strong>
\n <\/sup>
\n Annual Roth Conference<\/strong>
\n
Date: March 15, 2021
Time: 5:30 p.m. ET
Format: Fireside Chat (live)<\/p>\n

\n Oppenheimer 31<\/strong>
\n
\n st<\/strong>
\n <\/sup>
\n Annual Healthcare Conference<\/strong>
\n
Date: March 16, 2021
Time: 4:30 p.m. ET
Format: Corporate Presentation (live)<\/p>\n

Webcasts of the presentations will be available on the \u201cEvents and Presentations<\/a>\u201d section of the Clene website.<\/p>\n

\n About Clene<\/strong>\n <\/p>\n

Clene, a clinical-stage biopharmaceutical company focused on neurodegenerative disease, has innovated a novel nanotechnology platform to create a new class of drugs\u2014bioenergetic nanocatalysts. Clene\u2019s lead drug candidate, CNM-Au8, is a concentrated nanocrystalline gold (Au) suspension that drives critical cellular bioenergetic reactions in the CNS. CNM-Au8 increases cellular energy to accelerate neurorepair and improve neuroprotection. Currently, CNM-Au8 is being investigated for efficacy and safety in a Phase 3 registration trial for ALS and in Phase 2 trials for multiple sclerosis and Parkinson\u2019s disease. Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. The company is based in Salt Lake City, Utah with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com<\/a>.<\/p>\n

\n Forward-Looking Statements <\/strong>\n <\/p>\n

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Clene’s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “might” and “continues,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant known and unknown risks and uncertainties, many of which are beyond Clene\u2019s control and could cause actual results to differ materially and adversely from expected results. Factors that may cause such differences include Clene\u2019s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; Clene\u2019s ability to achieve commercial success for its marketed products and drug candidates, if approved; Clene\u2019s ability to obtain and maintain protection of intellectual property for its technology and drugs; Clene\u2019s reliance on third parties to conduct drug development, manufacturing and other services; Clene\u2019s limited operating history and its ability to obtain additional funding for operations and to complete the licensing or development and commercialization of its drug candidates; the impact of the COVID-19 pandemic on Clene\u2019s clinical development, commercial and other operations, as well as those risks more fully discussed in the section entitled \u201cRisk Factors\u201d in Clene\u2019s recently filed registration statement on Form S-4, as well as discussions of potential risks, uncertainties, and other important factors in Clene\u2019s subsequent filings with the U.S. Securities and Exchange Commission. Clene undertakes no obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, subject to applicable law. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.<\/p>\n

Media Contact
Andrew Mielach
LifeSci Communications
(646) 876-5868
amielach@lifescicomms.com<\/p>\n

Investor Contact
Bruce Mackle
LifeSci Advisors, LLC
(929) 469-3859
bmackle@lifesciadvisors.com<\/p>\n

Source: Clene Inc.<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SALT LAKE CITY, March 03, 2021 (GLOBE NEWSWIRE) — Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, \u201cClene\u201d) today announced that its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of neurodegenerative disease using nanocatalysis, will present at the following upcoming investor conferences: H.C. Wainwright Global Life Sciences Conference A pre-recorded presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. ET on March 9, 2021. 33 rd Annual Roth Conference Date: March 15, 2021Time: 5:30 p.m. ETFormat: Fireside Chat (live) Oppenheimer 31 st Annual Healthcare Conference Date: March 16, 2021Time: 4:30 p.m. ETFormat: Corporate Presentation (live) Webcasts of the presentations will be available on the \u201cEvents and … <\/p>\n

Continue reading “Clene Nanomedicine to Present at Upcoming Virtual Investor Conferences”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-450002","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nClene Nanomedicine to Present at Upcoming Virtual Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clene Nanomedicine to Present at Upcoming Virtual Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SALT LAKE CITY, March 03, 2021 (GLOBE NEWSWIRE) — Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, \u201cClene\u201d) today announced that its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of neurodegenerative disease using nanocatalysis, will present at the following upcoming investor conferences: H.C. Wainwright Global Life Sciences Conference A pre-recorded presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. ET on March 9, 2021. 33 rd Annual Roth Conference Date: March 15, 2021Time: 5:30 p.m. ETFormat: Fireside Chat (live) Oppenheimer 31 st Annual Healthcare Conference Date: March 16, 2021Time: 4:30 p.m. ETFormat: Corporate Presentation (live) Webcasts of the presentations will be available on the \u201cEvents and … Continue reading "Clene Nanomedicine to Present at Upcoming Virtual Investor Conferences"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-03T21:08:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MjUzMSM0MDQzMzkxIzUwMDA3NjMxOA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Clene Nanomedicine to Present at Upcoming Virtual Investor Conferences\",\"datePublished\":\"2021-03-03T21:08:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences\\\/\"},\"wordCount\":665,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MjUzMSM0MDQzMzkxIzUwMDA3NjMxOA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences\\\/\",\"name\":\"Clene Nanomedicine to Present at Upcoming Virtual Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MjUzMSM0MDQzMzkxIzUwMDA3NjMxOA==\",\"datePublished\":\"2021-03-03T21:08:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MjUzMSM0MDQzMzkxIzUwMDA3NjMxOA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MjUzMSM0MDQzMzkxIzUwMDA3NjMxOA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clene Nanomedicine to Present at Upcoming Virtual Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clene Nanomedicine to Present at Upcoming Virtual Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Clene Nanomedicine to Present at Upcoming Virtual Investor Conferences - Market Newsdesk","og_description":"SALT LAKE CITY, March 03, 2021 (GLOBE NEWSWIRE) — Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, \u201cClene\u201d) today announced that its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of neurodegenerative disease using nanocatalysis, will present at the following upcoming investor conferences: H.C. Wainwright Global Life Sciences Conference A pre-recorded presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. ET on March 9, 2021. 33 rd Annual Roth Conference Date: March 15, 2021Time: 5:30 p.m. ETFormat: Fireside Chat (live) Oppenheimer 31 st Annual Healthcare Conference Date: March 16, 2021Time: 4:30 p.m. ETFormat: Corporate Presentation (live) Webcasts of the presentations will be available on the \u201cEvents and … Continue reading \"Clene Nanomedicine to Present at Upcoming Virtual Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-03T21:08:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MjUzMSM0MDQzMzkxIzUwMDA3NjMxOA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Clene Nanomedicine to Present at Upcoming Virtual Investor Conferences","datePublished":"2021-03-03T21:08:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences\/"},"wordCount":665,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MjUzMSM0MDQzMzkxIzUwMDA3NjMxOA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences\/","name":"Clene Nanomedicine to Present at Upcoming Virtual Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MjUzMSM0MDQzMzkxIzUwMDA3NjMxOA==","datePublished":"2021-03-03T21:08:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MjUzMSM0MDQzMzkxIzUwMDA3NjMxOA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MjUzMSM0MDQzMzkxIzUwMDA3NjMxOA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Clene Nanomedicine to Present at Upcoming Virtual Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/450002","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=450002"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/450002\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=450002"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=450002"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=450002"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}